Role of pH in tumor-trapping of the anticancer drug 5-fluorouracil

Advances in Enzyme Regulation

Volumn 40, Issue 1, 2000, Pages 63-80

  McSheehy, Paul M J ^a   Stubbs, Marion ^a   Griffiths, John R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BAFILOMYCIN; FLUOROURACIL; METHOTREXATE;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PH; PH MEASUREMENT; SOLID TUMOR;

ANIMALIA;

EID: 0034043163     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(99)00034-5     Document Type: Conference Paper

References (42)

1. J. M. BROWN and A. J. GIACCA, The unique physiology of solid tumours: opportunities and problems for cancer therapy, Cancer Res. 58, 1408-1416 (1998).
2. R. K. JAIN, Barriers to drug delivery in solid tumors, Sci. American 7, 42-49 (1994).
3. 2 gradients in solid tumors in vivo: high resolution measurements reveal a lack of correlation, Nature Med. 3, 177-182 (1997).
4. A. C. SARTORELLI, Therapeutic attack of hypoxic cells of solid tumors, Cancer Res. 48, 775-778 (1988).
5. D. SHWEIKI, A. ITIN, D. SOFFER and E. KESHET, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature 359, 843-845 (1992).
6. G. U. DACHS, A. V. PATTERSON, J. D. FIRTH, P. J. RATCLIFFE, K. M. S. TOWNSEND, I. J. STRATFORD and A. L. HARRIS, Targetting gene expression to hypoxic tumor cells, Nature Med. 3, 515-520 (1997).
7. R. DUNCAN, S. DIMITRIJEVIC and E. G. EVAGOROU, The role of polymer conjugates in the diagnosis and treatment of cancer, STP Pharma. Sciences 6, 237-263 (1996).
8. L. E. GERWECK and K. SEETHARAMAN, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, Cancer Res. 56, 1194-1198 (1996).
9. M. STUBBS, L. M. RODRIGUES, F. A. HOWE, J. WANG, K. S. JEONG, R. L. VEECH and J. R. GRIFFITHS, The metabolic consequences of a reversed pH gradient in rat tumours, Cancer Res. 54, 4011-4016 (1994).
10. M. STUBBS, P. M. J. MCSHEEHY and J. R. GRIFFITHS, Causes and consequences of acid pH in tumors: a magnetic resonance study, Adv. Enzyme Reg. 39, 13-30 (1999).
11. M. STUBBS, P. M. J. MCSHEEHY, J. R. GRIFFITHS and C. L. BASHFORD, Tumour pH - causes and consequences of tumour acidity and implications for treatment, Molecular Med. Today 6, 15-19 (2000).
12. S. V. KOZIN and L. E. GERWECK, Cytotoxicity of weak electrolytes after the adaptation of cells to low pH: role of the transmembrane pH gradient, Brit. J. Cancer 77, 1580-1585 (1998).
13. A. GABR, A. KUIN, M. AALDERS, H. EL-GAWLY and L. A. SMETS, Cellular pharmacokinetics of camptothecin and topotecan at normal and acidic pH, Cancer Res. 57, 4811-4816 (1997).
14. R. M. WOHLHUETER, R. S. MCIVOR and P. G. W. PLAGEMANN, Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells, J. Cellular Physiol. 104, 309-319 (1980).
15. C. HEIDELBERGER, P. V. DANENBERG and R. G. MORAN, Fluorinated pyrimidines and their nucleosides, Adv. Enzymol. 54, 57-119 (1983).
16. S. P. ROBINSON, S. BARTON, P. M. J. MCSHEEHY and J. R. GRIFFITHS, Nuclear magnetic resonance spectroscopy of cancer, Brit. J. Radiology 70, S60-S69 (1997).
17. 19F nuclear magnetic resonance spectroscopy pharmacokinetics, J. Clin. Oncol. 8, 1868-1873 (1990).
18. C. A. PRESANT, W. WOLF, C. WALUCH, C. WISEMAN, P. KENNEDY, D. BLAYNAY and R. R. BRECHNER, Association of intratumoral pharmacokinetics of 5-fluorouracil with clinical response, The Lancet 343, 1184-1185 (1994).
19. A. S. E. OJUGO, P. M. J. MCSHEEHY, M. STUBBS, G. ALDER, C. L. BASHFORD, R. J. MAXWELL, M. O. LEACH, I. R. JUDSON and J. R. GRIFFITHS, Influence of pH on the uptake of 5-Fluorouracil into isolated tumour cells, Brit. J. Cancer 77, 873-879 (1998).
20. P. J. M. MCSHEEHY, S. P. ROBINSON, A. S. E. OJUGO, M. B. CANNELL, M. O. LEACH, I. R. JUDSON and J. R. GRIFFITHS, Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumours: a magnetic resonance study in vivo, Cancer Res. 58, 1185-1194 (1998).
21. R. J. ORDIDGE, A. CONNELLY and J. A. B. LOHMAN, Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy, J. Magn. Reson. 66, 283-294 (1986).
22. 31P MRS, Soc. Magn. Reson. 3, 1337 (1994).
23. 31P MRS in murine tumours, Brit. J. Cancer 72, 905-911 (1995).
24. 31P NMR signals using the variable projection method and prior knowledge, Magn. Reson. Med. 6, 92-96 (1988).
25. T. FRENZEL, S. KOHLER, H. BAUER, U. NIEDBALLA and H. J. WEINMANN, Non-invasive in vivo measurements using a fluorinated pH probe and fluorine-19 magnetic resonance spectroscopy, Invest. Radiol. 29, S220-S222 (1994).
26. A. ROOS and W. F. BORON, Intracellular pH, Physiol. Rev. 61, 296-434 (1981).
27. 31P magnetic resonance spectroscopy, Eur. J. Cancer 33, 2418-2427 (1997).
28. E. J. BOWMAN, A. SIEBERS and K. ALTENDORF, Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells and plant cells, Proc. Natl. Acad Sci. 85, 7972-7976 (1988).
29. + ATPases are functionally expressed in plasma membranes of human tumor cells, Am. J. Physiol. 265, C1015-C1029 (1993).
30. 1 increases the extracellular pH of pituitary tumours and inhibits their growth in vivo, Proc. Amer. Assoc. Cancer Res. 39, 1539 (1998).
31. T. OHTA, H. ARAKAWA, F. FUTAGAMI, S. FUSHIDA, H. KITAGAWA, M. KAYAHARA, T. NAGAKAWA, I. MIYAZAKI, M. NUMATA and S. OHKUMA, A new strategy for the therapy of pancreatic cancer by a proton pump inhibitor, Japanese J. Cancer & Chemother. 23, 1660-1664 (1996).
32. R. A. GATENBY and E. T. GAWLINSKI, A reaction-diffusion model of cancer invasion, Cancer Res. 56, 5745-5753 (1996).
33. T. J. DUNN, R. D. BRAUN, W. E. RHEMUS, G. L. ROSNER, T. W. SECOMB, G. M. TOZER, D. J. CHAPLIN and M. W. DEWHIRST, The effects of hyperoxic and hypercarbic gases on tumour blood flow, Brit. J. Cancer 80, 117-126 (1999).
34. S. P. ROBINSON, F. A. HOWE and J. R. GRIFFITHS, Noninvasive monitoring of carbogen-induced changes in tumour blood flow and oxygenation by functional magnetic resonance imaging, Int. J. Radiat. Oncol. Biol. Phys. 33, 855-859 (1995).
35. K. G. HELMER, S. HANS and C. H. SOTAK, On the correlation between the water diffusion coefficient and oxygen tension in RIF-1 tumors, NMR Biomed. 11, 120-130 (1998).
36. N. RAGHUNAND, X. HE, R. VAN SLUIS, B. MAHONEY, B. BAGGETT and C. W. TAYLOR et al., Enhancement of chemotherapy by manipulation of tumour pH, Brit. J. Cancer 80, 1005-1011 (1999).
37. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study, Ann. Oncol. 4, 597-602 (1993).
38. 19F NMR study during 5FU chemotherapy in patients with metastases of colorectal adenocarcinoma, Mag. Reson. Imaging 12, 497-511 (1994).
39. A. KUIN, M. AALDERS, M. LAMFERS, D. J. VAN ZUIDAM, M. ESSERS, J. H. BEIJNEN and L. A. SMETS, Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine and its analogue benzylguanidine, Brit. J. Cancer 79, 793-801 (1999).
40. K. W. NEWELL, P. WOOD, I. STRATFORD and I. TANNOCK, Effects of agents which inhibit the regulation of intracellular pH on murine solid tumors, Brit. J. Cancer 66, 311-317 (1992).
41. C. L. BASHFORD and C. A. PASTERNAK, Plasma membrane potential of Lettre cells does not depend on cation gradients but on pumps, J. Membrane Biol. 79, 275-284 (1984).
42. R. HARRISON and G. G. LUNT, Biological Membranes, Structure and Function. 2nd edition. Blackie, London & Glasgow, UK, (1980).